Category: 3. Business

  • DOJ files antitrust suit against New York hospital over contract restrictions – Dentons

    1. DOJ files antitrust suit against New York hospital over contract restrictions  Dentons
    2. Justice Department Files Antitrust Lawsuit Against NewYork-Presbyterian  WSJ
    3. Hospitals feel the heat over anticompetitive contracting  Axios
    4. What DOJ’s recent antitrust lawsuit means for health systems  Modern Healthcare
    5. UFT Warns Teachers Could Lose NewYork‑Presbyterian Coverage  Hoodline

    Continue Reading

  • Reese’s chocolate heir accuses Hershey of altering recipes: ‘It wasn’t real peanut butter’ | Chocolate

    Reese’s chocolate heir accuses Hershey of altering recipes: ‘It wasn’t real peanut butter’ | Chocolate

    The grandson of HB Reese, the inventor of Reese’s Peanut Butter Cups, has accused the chocolate giant Hershey of faking a pledge to investors to switch back the recipes of its popular products – including KitKat – to the original milk and dark chocolate ones.

    A confectionary-focused dust-up between Brad Reese and the $42bn Pennsylvania-based company began in February when Reese, 70, accused the company of “quietly replacing” the ingredients – or “architecture” – in his grandfather’s invention with cheaper “compound coatings” and “peanut-butter-style crèmes”.

    At a recent Hershey investor conference, the company said it would change about 3% of select products to the original recipes but maintained it had never altered the renowned Reese’s Peanut Butter Cups.

    The company’s chief growth officer, Stacy Taffet, said Hershey was “transitioning our sweets portfolio to colors from natural sources, and ensuring that all Hershey’s and Reese’s offerings are consistent with their brand’s classic milk and dark chocolate recipes”. The changes are planned to come into effect by next year.

    But Reese accused the company of “ingredient drift across flagship brands” and described the move “as a board level accountability problem” that caused shareholders to sell stock. “Your consumers are revolting,” he added.

    Reese further told the New York Times he is not satisfied and the changes were not coming quickly enough. “This is just a PR stunt; there’s no victory here,” he said in an interview with outlet. “If they were serious, they would do it right away.”

    The company has said the changes were already under way but not in response to Reese’s criticism, saying it had previously decided to revert to classic recipes after seeing a 25% increase in research and development to fund talent, technology and nutrition science.

    The issue has become something of a crusade for Reese, who alleges Hershey changed sometime after buying the Reese’s brand in the 1960s.

    In his original complaint to the company, issued on Valentine’s Day on the LinkedIn social media platform, Reese railed that recipes were “being rewritten, not by storytellers, but by formulation decisions that replace Milk Chocolate with compound coatings and Peanut Butter with peanut‑butter‑style crèmes”.

    Reese said he’d noticed the difference in taste when he tried Reese’s Unwrapped Chocolate Peanut Butter Creme Mini Hearts.

    “I opened it up, and I had about two of them, and I had to spit them out,” he said. “I dumped the entire contents into my kitchen garbage can, and I kept the pouch. I checked it and it wasn’t milk chocolate, it wasn’t real peanut butter.

    “I’ve never in my entire life spit out a Reese’s product.”

    But Reese’s family do not support his complaints. They said in a statement provided to USA Today by Hershey that “his statements and opinions are entirely his own and do not reflect the view or position of our family”.

    “We continue to respect The Hershey Company, its leadership, and its longstanding role in our community,” they added. “We believe HB Reese would take great pride in the products produced under his name today and in the integrity with which the brand continues to be managed.”

    Brad Reese didn’t accept that and accused the company of trying to “shoot the messenger”.

    “Hershey can issue all the statements it wants,” he fumed on LinkedIn. “They changed the REESE’S product. They got caught. And now they’re trying to manage perception instead of fixing the problem. The evidence chain isn’t going away.”

    Continue Reading

  • FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

    FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL

    The U.S. Food and Drug Administration (FDA) has granted traditional approval to the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (Tecartus) for adult patients with relapsed or refractory mantle cell lymphoma (MCL). The full approval now includes efficacy, safety, and pharmacokinetic data from cohort 3 of the ZUMA-2 study (ClinicalTrials.gov identifier NCT05537766) in patients whose disease becomes relapsed or refractory after one or more lines of therapy and who are Bruton’s tyrosine kinase (BTK) inhibitor–naive.

    This action converts the relapsed or refractory MCL indication to full approval based on the totality of evidence from ZUMA-2, including confirmatory data from cohort 3, which demonstrated high response rates, durable efficacy outcomes, and a manageable safety profile consistent with prior experience. This milestone fulfills the postmarketing requirement for verification and description of clinical benefit in a confirmatory trial under the FDA’s Accelerated Approval pathway for brexucabtagene autoleucel in relapsed/refractory MCL.

    “The full approval of [brexucabtagene autoleucel] in relapsed or refractory MCL, along with the inclusion of cohort 3 data in the label, reinforces our confidence in the overall profile of brexucabtagene autoleucel,” said Michael Wang, MD, ZUMA-2 lead investigator and Professor in the Department of Lymphoma and Myeloma, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. “The cohort 3 results showed high response rates, including deep remissions, in patients who were BTK inhibitor–naive, with a manageable safety profile consistent with prior experience. These data provide important information to help guide treatment decisions in the relapsed or refractory setting for appropriate patients.”

    MCL is a rare form of non-Hodgkin lymphoma that arises from cells originating in the “mantle zone” of the lymph node and predominantly affects men over the age of 60. Approximately 33,000 people worldwide are diagnosed with MCL each year. MCL is highly aggressive following relapse, with many patients’ disease progressing following therapy.

    More From ZUMA-2

    ZUMA-2 is a single-arm, open-label, multicenter study evaluating brexucabtagene autoleucel in adult patients with relapsed or refractory MCL. Cohorts 1 and 2 evaluated the therapy in patients who had previously received up to five lines of therapy, including anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody, and a BTK inhibitor. Cohort 3 evaluated brexucabtagene autoleucel in patients who had received up to five prior lines of therapy and were BTK inhibitor–naive. A total of 82 patients were treated in cohorts 1 and 2 and 86 patients were treated in cohort 3. The primary endpoint across the study was objective response rate per the Lugano Classification (2014), as assessed by an Independent Radiologic Review Committee.

    The objective response rate in cohort 1 was 87%; in cohort 3, it was 91%. The complete remission rate was 62% vs 79%; in both cohorts, the median duration of response was not reached (the median follow-up for duration of response at the time of the primary analysis was 8.6 months in cohort 1 vs 23.0 months in cohort 3).

    In the updated U.S. Prescribing Information, MCL safety data are pooled across cohorts 1–3 (n = 168). In this pooled MCL population, cytokine-release syndrome (CRS) occurred in 93% of patients, including grade ≥ 3 CRS in 12%; the median time to onset was 4 days and the median duration was 7 days. Neurologic events occurred in 80% of patients, including grade ≥ 3 neurologic events in 33%; the median time to onset was 6 days and the median duration was 19 days. Infections of any grade occurred in 63% of patients, including grade ≥ 3 infections in 33%. In cohort 3, serious adverse reactions occurred in 65% of patients. The most common serious adverse reactions (occurring in > 2% of patients) were nonventricular arrhythmias, tachycardias, pyrexia, CRS, unspecified pathogen infections, viral infections, bacterial infections, fungal infections, musculoskeletal pain, motor dysfunction, encephalopathy, aphasia, tremor, seizure, delirium, hypoxia, hypotension, hemorrhage, and thrombosis.

    Continue Reading

  • A Look At NANO Nuclear Energy (NNE) Valuation After Recent Share Price Rebound

    A Look At NANO Nuclear Energy (NNE) Valuation After Recent Share Price Rebound

    Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

    NANO Nuclear Energy (NNE) is back on investor radars after a recent 4.8% daily gain, standing out against a month and past 3 months stretch of negative share price returns.

    See our latest analysis for NANO Nuclear Energy.

    That 4.8% 1 day share price return, with the stock now at $21.38, comes after a year to date share price return of negative 22.56% and a 1 year total shareholder return of negative 8.91%. This suggests recent momentum is improving from a weaker stretch.

    If this move in NANO Nuclear Energy has you looking across the sector, it could be a good moment to scan other nuclear related names using our 93 nuclear energy infrastructure stocks

    With NANO Nuclear Energy still showing weak recent returns despite a 4.8% daily jump and trading at a wide gap to the US$46.67 analyst target, you have to ask whether this is a real opportunity or whether the market is already pricing in future growth.

    The most followed narrative currently anchors NANO Nuclear Energy’s fair value at $46.67, which sits well above the latest close of $21.38 and frames that analyst gap in a very specific way.

    The focus on vertical integration in enrichment, conversion, transport and TRISO fuel supply aims to address expected bottlenecks in the nuclear fuel chain. This approach may give NANO more control over input costs and availability, with potential implications for future net margins.

    Read the complete narrative.

    Want to see what kind of revenue ramp and margin profile that narrative is assuming? The numbers rely on rapid top line growth and a future earnings multiple more often associated with high growth stories than early stage nuclear developers.

    Result: Fair Value of $46.67 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, you still need to weigh licensing and construction timing risks, as well as the reliance on future AI and industrial power demand that may not convert into projects.

    Find out about the key risks to this NANO Nuclear Energy narrative.

    If the mixed tone of this story has you on the fence, act while the data is fresh and weigh both sides with our 2 key rewards and 4 important warning signs

    If this story has caught your attention, do not stop here. Broaden your watchlist with fresh ideas pulled from different corners of the market.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include NNE.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Hydrogen Europe

    Hydrogen Europe